Insmed Incorporated (NASDAQ:INSM) – Equities research analysts at Svb Leerink boosted their Q2 2019 EPS estimates for Insmed in a report issued on Wednesday, June 12th. Svb Leerink analyst J. Schwartz now forecasts that the biopharmaceutical company will post earnings of ($0.56) per share for the quarter, up from their previous forecast of ($0.64). Svb Leerink also issued estimates for Insmed’s Q3 2019 earnings at ($0.70) EPS, Q4 2019 earnings at ($0.73) EPS, FY2019 earnings at ($2.94) EPS, FY2020 earnings at ($2.68) EPS, FY2021 earnings at ($1.31) EPS and FY2022 earnings at ($0.01) EPS.
Other analysts have also issued research reports about the stock. BidaskClub upgraded shares of Insmed from a “hold” rating to a “buy” rating in a research note on Friday, April 5th. HC Wainwright reiterated a “buy” rating and issued a $52.00 price objective (up previously from $43.00) on shares of Insmed in a research note on Tuesday, April 9th. Canaccord Genuity set a $44.00 price objective on shares of Insmed and gave the stock a “buy” rating in a research note on Friday, March 8th. ValuEngine lowered shares of Insmed from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, May 28th. Finally, JMP Securities upgraded shares of Insmed from a “market perform” rating to an “outperform” rating and set a $40.00 price target on the stock in a research report on Friday, February 15th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Insmed presently has a consensus rating of “Buy” and an average target price of $37.88.
NASDAQ:INSM opened at $24.71 on Friday. Insmed has a 1-year low of $11.31 and a 1-year high of $33.13. The company has a quick ratio of 4.69, a current ratio of 4.82 and a debt-to-equity ratio of 2.48.
Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.94) by ($0.02). The business had revenue of $21.90 million for the quarter, compared to analyst estimates of $19.61 million.
Several large investors have recently bought and sold shares of the company. Raymond James & Associates raised its stake in Insmed by 101.9% during the fourth quarter. Raymond James & Associates now owns 57,757 shares of the biopharmaceutical company’s stock worth $758,000 after purchasing an additional 29,150 shares during the period. Virtus ETF Advisers LLC raised its stake in Insmed by 23.0% during the fourth quarter. Virtus ETF Advisers LLC now owns 20,606 shares of the biopharmaceutical company’s stock worth $270,000 after purchasing an additional 3,855 shares during the period. Foresite Capital Management IV LLC raised its stake in Insmed by 9.8% during the fourth quarter. Foresite Capital Management IV LLC now owns 1,977,236 shares of the biopharmaceutical company’s stock worth $25,941,000 after purchasing an additional 176,649 shares during the period. SG Americas Securities LLC purchased a new position in Insmed during the fourth quarter worth about $221,000. Finally, Bellevue Group AG raised its stake in Insmed by 42.9% during the fourth quarter. Bellevue Group AG now owns 809,146 shares of the biopharmaceutical company’s stock worth $10,616,000 after purchasing an additional 242,845 shares during the period.
In other news, Director Donald J. Hayden, Jr. sold 6,286 shares of the firm’s stock in a transaction dated Tuesday, April 9th. The shares were sold at an average price of $32.99, for a total value of $207,375.14. Following the transaction, the director now directly owns 68,483 shares of the company’s stock, valued at $2,259,254.17. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Orlov S. Nicole Schaeffer sold 12,000 shares of the firm’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $23.24, for a total transaction of $278,880.00. Following the completion of the transaction, the insider now directly owns 36,350 shares in the company, valued at $844,774. The disclosure for this sale can be found here. 4.95% of the stock is owned by company insiders.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.